

Human Neutrophil Elastase Induce Interleukin-10 Expression in Peripheral Blood Mononuclear Cells through Protein Kinase C Theta/Delta and Phospholipase Pathways

Jin Kawata, Ph.D, Rui Yamaguchi, Ph.D., Takatoshi Yamamoto, M.Sc., Yasuji Ishimaru, M.D., Ph.D., Arisa Sakamoto, M.Sc., Manabu Aoki, Ph.D., Masafumi Kitano, M.Sc., Misako Umehashi, Ph.D., Eiji Hirose, M.Sc., Yasuo Yamaguchi, M.D., Ph.D.*

Graduate School of Medical Science, Kumamoto Health Science University, Kumamoto, Japan

*Corresponding Address: Graduate School of Medical Science, Kumamoto Health, Science University, Kitaku Izumi-machi 325, Kumamoto 861-5598, Japan
Email: yamaguti@kumamoto-hsu.ac.jp

Received: 8/Jan/2015, Accepted: 15/Mar/2015

Abstract

Objective: Neutrophils have an important role in the rapid innate immune response, and the release or active secretion of elastase from neutrophils is linked to various inflammatory responses. Purpose of this study was to determine how the human neutrophil elastase affects the interleukin-10 (IL-10) response in peripheral blood mononuclear cells (PBMC).

Materials and Methods: In this prospective study, changes in IL-10 messenger RNA (mRNA) and protein expression levels in monocytes derived from human PBMCs were investigated after stimulation with human neutrophil elastase (HNE). A set of inhibitors was used for examining the pathways for IL-10 production induced by HNE.

Results: Reverse transcription polymerase chain reaction (RT-PCR) showed that stimulation with HNE upregulated *IL-10* mRNA expression by monocytes, while the enzyme-linked immunosorbent assay (ELISA) revealed an increase of IL-10 protein level in the culture medium. A phospholipase C inhibitor (U73122) partially blunted the induction of *IL-10* mRNA expression by HNE, while *IL-10* mRNA expression was significantly reduced by a protein kinase C (PKC) inhibitor (Rottlerin). A calcium chelator (3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester: TMB-8) inhibited the response of *IL-10* mRNA to stimulation by HNE. In addition, pretreatment with a broad-spectrum PKC inhibitor (Ro-318425) partly blocked the response to HNE. Finally, an inhibitor of PKC theta/delta abolished the increased level of *IL-10* mRNA expression.

Conclusion: These results indicate that HNE mainly upregulates *IL-10* mRNA expression and protein production in monocytes via a novel PKC theta/delta, although partially via the conventional PKC pathway.

Keywords: Interleukin-10, PBMC, Protein kinase C

Cell Journal(yakhteh), Vol 17, No 4, Winter 2016, Pages: 692-700

Citation: Kawata J, Yamaguchi R, Yamamoto T, Ishimaru Y, Sakamoto A, Aoki M, Kitano M, Umehashi M, Hirose E, Yamaguchi Y. Human neutrophil elastase induce interleukin-10 expression in peripheral blood mononuclear cells through protein kinase c theta/delta and phospholipase pathways. Cell J. 2016; 17(4): 692-700.

Introduction

Neutrophils are an important part of the rapid innate immune response that accompanies acute inflammation. Neutrophils release the contents

of various granules while migrating to sites of inflammation, and these granule proteins play a central role in the early inflammatory response. The serine proteases cathepsin G, human leu-

kocyte elastase, and proteinase 3 are abundant in neutrophil granules (1). These proteases regulate inflammatory processes by activating specific receptors and modulating the production of various cytokines (2). Human neutrophil elastase (HNE) is a 29 kDa serine endoprotease from the proteinase S1 family that forms a single 238-amino acid peptide chain with four disulfide bonds. Elastase released from activated neutrophils can cause tissue destruction (3-5), and is an important mediator of inflammatory tissue damage that is involved in the degradation of extracellular matrix components such as elastin, fibronectin, proteoglycan, and collagen (6). Serine proteases play various important physiological roles via G protein-coupled protease-activated receptors (PARs). PAR2 is a trypsin-activated member of the family of G-protein-coupled PARs (7).

Inflammatory response-associated neutrophil proteinases may influence cell signaling by targeting PAR-2. It was reported that trypsin and the PAR-2 synthetic peptide agonist Ser-Leu-Ile-Gly-Arg-Leu (SLIGRL) induce Ca^{2+} mobilization, a transient increase of the inositol 1, 4, 5-trisphosphate (IP3) level, and translocation of protein kinase C (PKC) (8). Binding of HNE to PAR-2 increases the cytosolic calcium concentration and subsequently activates PKC, resulting in the secretion of mucin 5AC (MUC5AC) by airway epithelial cells (9). It was recently suggested that PAR-2 is involved in proinflammatory immune responses. Monocytes are well known to produce a range of pro-inflammatory and anti-inflammatory mediators. After activation by PAR-2, monocytes produce interleukin (IL)-6, IL-8, and IL-1 β , suggesting that PAR-2 may have a pro-inflammatory role (10). However, it is also possible that monocytes activated by PAR-2 produce IL-10 and thus have an anti-inflammatory effect. Accordingly, the present study investigated the possibility that PAR-2 participates in the regulation of anti-inflammatory responses through the induction of IL-10 production by monocytes stimulated

with HNE. The PKC family of serine/threonine kinases is composed of 10 isoforms that are divided into three classes, which are conventional (alpha, beta1, beta 2, and gamma), novel (delta, epsilon, theta, and eta) and atypical (xi and zeta) isoforms. We also examined the roles of these PKC isoforms in IL-10 production by monocytes.

Materials and Methods

Ethical considerations for prospective study

All human materials such as the peripheral blood cells used in this study were collected from male (n=15) and female (n=15) non-smoking healthy volunteers aged 26-33 after their informed consent was obtained. The protocol of this study was approved by Institutional Review Board of Kumamoto Health Science University, and the study was conducted in accordance with the Declaration of Helsinki.

Reagents

HNE with 81 U/mg of activity was purchased from SERVA Electrophoresis (Heidelberg, Germany). 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester (TMB-8, Sigma-Aldrich, Canada), A23187 (Santa Cruz Biotechnology, USA), Rottlerin Tumor necrosis factor- α (TNF- α) protease inhibitor I (TAPI-1), U73122, R59022 (Merck Millipore, USA), and pyrrolidinedithiocarbamate (PDTC, BioVision, USA) were employed to investigate the intracellular signal transduction pathways involved in *IL-10* mRNA expression. The actions of these reagents are summarized in table 1.

In addition, PKC inhibitors including Ro-318425 (Merck Millipore), Go 6976, Go 6983, and CGP 41251 (Tocris Bioscience, UK), as well as a PKC theta/delta inhibitor (Merck Millipore) were utilized to investigate the roles of PKC isoforms in IL-10 production. The PKC isoform-specific inhibition profile of these reagents is summarized in table 2.

Table 1: Functional characteristics of chemical agents used

| Chemical agents | Functions |
|-----------------|--|
| Rottlerin | Protein kinase C inhibitor |
| TAPI-1 | A disintegrin and metalloproteinase inhibitor (ADAM) |
| U73122 | Phospholipase C inhibitor |
| A23187 | Calcium ionophore PKC-activating agent |
| TMB-8 | Intracellular calcium antagonist |
| R59022 | A diacylglycerol kinase inhibitor |
| PDTC | An inhibitor of NF-kB |

TAPI-1; Tumor necrosis factor-alpha (TNF- α) protease inhibitor I, TMB-8; 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester and PDTC; Pyrrolidinedithiocarbamate.

Table 2: Isoform-specific protein kinase C (PKC) inhibitors

| Reagent | PKC isoform | | | | | Reference no. |
|-------------------------------|--------------|---------------|----------------|--------------|---------------------------|---------------|
| Ro-318425 | PKC α | PKC β I | PKC β II | PKC γ | | 11-13 |
| Go 6976 | PKC α | PKC β I | | | | 14, 15 |
| Go 6983 | PKC α | PKC β I | | PKC γ | PKC δ | 16, 17 |
| CGP41251 | PKC α | PKC β I | PKC β II | PKC γ | PKC δ | 18, 19 |
| PKC θ/δ inhibitor | | | | | PKC δ PKC θ | 20, 21 |

Xestospongin C, which antagonizes the calcium-releasing action of IP₃ at the receptor level, was obtained from Sigma-Aldrich, USA. Each reagent solution was negative for endotoxin according to the Endospey test (22, 23).

Isolation of monocytes from peripheral blood mononuclear cells (PBMCs)

Lymphocyte medium for thawing (BBL YMPH1) was obtained from Zen-Bio, Inc. (Research Triangle Park, NC). PBMCs were isolated as described previously (24). Briefly, heparinized blood samples were obtained from nonsmoking healthy volunteers and were diluted 1:1 with pyrogen-free saline. PBMCs were isolated immediately after collection using Lymphoprep gradients (Axis-Shield PoC As, Norway). Then, cells were suspended with BBL YMPH1 and incubated for 3 hours. For monocyte isolation by plastic adherence, 1×10^6 cells per well were distributed into 12-well plates (Corning Inc. Costar, USA) and allowed to adhere in a 5% CO₂ incubator at 37°C for 2 hours. Monocytes were further enriched by virtue of their attachment to a cul-

ture plate for 2 hours and washed 3 times with warm phosphate-buffered saline (PBS, Invitrogen, USA) to remove nonadherent cells. Then, monocytes were cultured in complete medium consisting of RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), and 10 μ g/mL gentamicin (Invitrogen, USA) at 37°C in 5% CO₂ humidified air. The adherent monocytes were recovered with a cell scraper. The purity of monocytes was evaluated by fluorescent staining with CD14-phycoerythrin (PE) mouse anti-human monoclonal antibody (Life technologies, USA) and fluorescence-activated cell sorting (FACS) analysis. The recovery of monocytes was also evaluated by trypan blue staining and counted using a microscope (Zeiss, Germany). Only isolated CD14⁺ monocytes of >85% purity were used for each experiment. After monocytes were resuspended in RPMI-1640 medium supplemented with 25 mM HEPES (Sigma-Aldrich, St. Louis, MO), 100 mmol/L L-glutamine (Invitrogen, Carlsbad), 100 U/mL penicillin 100 μ g/mL streptomycin (Biowest LLC, USA), and 10% FCS, the cells were stimulated with HNE for 6 hours.

Extraction of RNA and reverse transcription polymerase chain reaction (RT-PCR)

Extraction was done with 500 μ L of TRIzol™ reagent (Invitrogen, France), and total RNA was isolated and precipitated according to the manufacturer's instructions. Then 1 μ g of total RNA was subjected to reverse transcription using random heptamer primers with Moloney murine leukemia virus (Invitrogen, USA). Next, 1 μ L of reverse-transcribed RNA was amplified by polymerase chain reaction (PCR) on an ABI PRISM 7000 thermal cycler (Applied Biosystems, USA) using the Taqman™ Master Mix Kit. Quantification of target mRNA was performed by comparing the number of cycles required to reach the reference and target threshold values (25). Monocytes were incubated with HNE (0 or 5 μ g/mL) for 6 hours, after which *IL-10* mRNA expression was analysed by RT-PCR. The primer sequences used were as follows:

IL-10

F: 5'-ATGCCCAAGCTGAGAACCAAGAC-3'
R: 5'-TCTCAAGGGCTGGGTCAGCTATCCCA-3'

β -actin

F: 5'-GTGGGGCGCCCCAGGCACCA-3'
R: 5'-CTCCTTAATGTCACGCACGATTTC-3'

The PCR conditions were as follows: for *IL-10*, 35 cycles (94°C for 60 seconds, 60°C for 30 seconds, and 72°C for 60 seconds) and for *β -actin*, 40 cycles (94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds) were used. The PCR products were analyzed on agarose gels.

Enzyme-linked immunosorbent assay (ELISA) for Interleukin-10

After monocytes were stimulated with HNE for 6 hours, the level of IL-10 protein in the supernatant was measured by enzyme-linked immunosorbent assay (ELISA) with an anti-IL-10 monoclonal antibody (Abcam Inc., USA).

Protein kinase C activity assay

PKC kinase activity assay kit was obtained from Abcam Inc. (USA). This kit is based on a solid phase ELISA that utilizes a specific synthetic peptide as a substrate for PKC and a polyclonal antibody that recognizes the phosphorylated form of the substrate. Monocytes were incubated for 6

hours with or without HNE (5 μ g/mL). Then, cells were lysed in 1 mL of lysis buffer, and 30 μ L were tested for PKC activity.

Statistical analysis

Data are expressed as the mean \pm SD. Analysis of variance and the t test of independent means were used to determine differences between multiple groups and differences between two groups, respectively. When the F ratio was significant, mean values were compared using a post hoc Bonferroni's test. A P value < 0.05 was considered to indicate a significant difference in all analyses.

Results

To examine *IL-10* response in PBMC, we detect *IL-10* expression by semi-quantitative RT-PCR with HNE treatment for 6 hours at concentrations of 0, 1, and 5 μ g/mL. The relative *IL-10* expression is around 2 times higher with HNE treatment at 5 μ g/mL than control (0 μ g/mL). Consistent with the data revealing PBMCs increase *IL-10* expression after HNE treatment (Fig.1), secretion IL-10 protein are also increased around 10 times in supernatants after HNE treatment by ELISA (Fig.2). The U73122 (phospholipase C inhibitor) significantly reduced the response of *IL-10* mRNA expression to stimulation with HNE. In contrast, R59022 (a diacylglycerol kinase inhibitor) had no effect on *IL-10* mRNA levels. Similarly, neither a TNF- α converting enzyme (TACE) inhibitor, TAPI-1, nor an inhibitor of nuclear factor-kappa B (NF- κ B), PDTC, reduced *IL-10* mRNA expression by HNE-stimulated monocytes (Fig.3). However, the calcium chelator, like TMB-8, completely inhibited the response of *IL-10* mRNA to HNE, although calcium ionophore A18237 (a PKC-activating agent) did not augment *IL-10* mRNA expression. Interestingly, the PKC inhibitor Rottlerin blunted the increase of *IL-10* mRNA expression after stimulation of monocytes with HNE (Fig.4). Monocytes were incubated for 6 hours with or without HNE (5 μ g/mL) and then PKC activity was determined. PKC activity in lysates obtained from monocytes stimulated with HNE was significantly higher than untreated control cells (Fig.5).

Next, the effect of various PKC isoform inhibitors on *IL-10* mRNA expression was examined by RT-PCR. Ro-318425 (1 μ M/mL) partially inhibited the increase of *IL-10* mRNA expression in

monocytes exposed to HNE and more effectively inhibited the response of *IL-10* mRNA at a higher concentration (5 μ M/mL). Go 6976 (1 μ M/mL) had no influence on the increase of *IL-10* mRNA in monocytes exposed to HNE, but partially inhibited the response of *IL-10* mRNA at a higher con-

centration (5 μ M/mL). Similarly, Go 6983 had no effect at a concentration of 1 μ M/mL, but partially inhibited *IL-10* mRNA expression at a concentration of 5 μ M/mL. Interestingly, addition of a PKC theta/delta inhibitor (5 μ M/mL) completely abolished *IL-10* expression (Fig.6).




Fig.1: RT-PCR detection of *IL-10* mRNA in monocytes stimulated with HNE. When monocytes were stimulated with HNE (0, 1, or 5 μ g/mL), *IL-10* mRNA expression increased in a dose-dependent manner. The relative density of the bands was normalized to β -actin. Data were obtained from three individuals in each group and represent the mean \pm SD. *, $P < 0.01$, **, $P < 0.05$, RT-PCR; Reverse transcription polymerase chain reaction, *IL-10*; Interleukin-10 and HNE; Human neutrophil elastase.




Fig.2: Measurement of IL-10 protein levels by ELISA. IL-10 levels were significantly increased in culture supernatants of monocytes stimulated with HNE (1 or 5 μ g/mL) compared with the control (0 μ g/mL HNE). Data were obtained from three individuals and represent the mean \pm SD. *, $P < 0.01$, IL-10; Interleukin-10, HNE; Human neutrophil elastase and ELISA; Enzyme-linked immunosorbent assay.




Fig.3: Effect of TAPI-1, U73122, R59022, and PDTC on *IL-10* mRNA expression. U73122 blunted the increase of *IL-10* mRNA in HNE-stimulated monocytes. The relative density of the bands was normalized to β -actin. Data were obtained from three individuals in each group and represent the mean \pm SD. *, $P < 0.01$, **, $P < 0.05$, N.S.; Not significant, TAPI-1; Tumor necrosis factor-alpha (TNF- α) protease inhibitor I, PDTC; Pyrrolidinedithiocarbamate, *IL-10*; Interleukin-10 and HNE; Human neutrophil elastase.




Fig.4: Effect of TMB-8, A23187, and Rottlerin on *IL-10* mRNA expression. TMB-8 partially blocked the increase of *IL-10* mRNA in HNE-stimulated monocytes and Rottlerin abolished it. The relative density of the bands was normalized to β -actin. Data were obtained from three individuals in each group and represent the mean \pm SD. *, $P < 0.01$, TMB-8; 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester, *IL-10*; Interleukin-10 and HNE; Human neutrophil elastase.




Fig.5: PKC activity assay. Monocytes were incubated for 6 hours with or without HNE (5 µg/mL) and then PKC activity was determined. PKC activity in lysates obtained from monocytes stimulated with HNE was significantly higher than untreated control cells. Data were obtained from three individuals in each group and represent the mean ± SD. *, P<0.01, PKC; Protein kinase C, HNE; Human neutrophil elastase and O.D.; Optical density.





Fig.6: Effect of various PKC isoform inhibitors on *IL-10* mRNA expression by monocytes after HNE stimulation. Ro-318425 partially inhibited the increase of *IL-10* mRNA expression in response to HNE, while the PKC theta/delta inhibitor completely abolished it. The relative density of the bands was normalized to *β-actin*. Data were obtained from three individuals in each group and represent the mean ± SD. *, P<0.01, PKC; Protein kinase C, *IL-10*; Interleukin-10 and HNE; Human neutrophil elastase.

Discussion

The present study demonstrated that the phospholipase C inhibitor, U73122, blunted the up-regulation of *IL-10* mRNA expression in response to stimulation of monocytes with HNE. U73122 is reported to be as specific inhibitor of G-protein-mediated phospholipase C activation (26). In addition, pre-incubation with TMB-8, a PKC inhibitor that is also an intracellular Ca^{2+} antagonist (27, 28), was more effective at inhibiting the response of *IL-10* mRNA to HNE stimulation.

These findings suggest that HNE upregulates *IL-10* expression in PBMCs by promoting intracellular Ca^{2+} influx and activating the phospholipase C signaling pathway.

Xestospongine C antagonizes the calcium-releasing action of IP_3 at the receptor level. Inositol phosphates are important signal transduction messengers that act via IP_3 receptors to promote the mobilization of Ca^{2+} from intracellular stores. Xestospongine C blocks the increase of intracellular calcium and also inhibits the Ca^{2+} ATPase pump in the sarcoplasmic reticulum (29). In the present study, xestospongine C did not affect the increase of *IL-10* mRNA expression in response to HNE stimulation. The protease-activated receptor (PAR) family of G protein-coupled receptors is activated by a unique mechanism that involves proteolytic unmasking of an N-terminal self-activating tethered ligand. Proteinases can either activate PAR signaling by unmasking the tethered ligand sequence or disarm the receptor for subsequent enzyme activation by cleavage downstream from this sequence (30).

Tumor necrosis factor- α converting enzyme (TACE) cleaves TNF at the Ala-76–Val-77 site and TACE expression has been detected on alveolar macrophages by flow cytometry. It is known that activation of the epidermal growth factor receptor and its downstream signaling cascade are involved in the production of mucin. TACE cleaves pro-transforming growth factor- α in airway epithelial cells to release its mature soluble form, which subsequently binds to and activates the epidermal growth factor receptor. Shao and Nadel (31) previously demonstrated that HNE induces MUC5AC mucin expression in human airway epithelial cells via a cascade that includes PKC, oxygen radicals, and TACE. However, TAPI-1 did not affect *IL-10* mRNA expression by monocytes in the present study. Instead, the present findings in-

dicated that *IL-10* production by monocytes involves a Rottlerin-sensitive pathway. Rottlerin has been employed as a selective inhibitor of protein kinase C delta in several studies (12, 32). In contrast, Soltoff (33) reported that Rottlerin did not block PKCdelta activity *in vitro*, although it blocked several other kinase and non-kinase proteins and strongly activated multiple Ca^{2+} -sensitive K^+ channels. In the present study, we employed a molecular approach to characterize the role of each PKC isoform in the regulation of HNE-induced *IL-10* expression by monocytes. Because the PKC isozyme family is clearly divided into three subgroups (conventional, novel, and atypical), the role of PKC isoforms from each subgroup in *IL-10* production was investigated. The broad-spectrum PKC inhibitor bisindolylmaleimide Ro-318425 (which inhibits conventional PKC isoforms) partially blocked upregulation of *IL-10* mRNA expression by HNE in a concentration-dependent manner. However, the Ca^{2+} -dependent PKC inhibitor Go 6976 (another inhibitor of conventional PKC isoforms) had less effect on the response of *IL-10* mRNA to HNE. Similarly, the broad-spectrum PKC inhibitor Go 6983 (a PKC β II inhibitor) partially blocked the increase of *IL-10* mRNA expression induced by HNE. Interestingly, a PKC theta/delta inhibitor (which inhibits novel PKC isoforms) strongly suppressed *IL-10* mRNA expression after HNE stimulation. These findings suggest that HNE upregulates *IL-10* expression in monocytes by promoting intracellular Ca^{2+} influx, activating phospholipase C, and preferentially activating the novel PKC signaling pathway over the conventional pathway.

Conclusion

Monocytes produce anti-inflammatory *IL-10* after stimulation with HNE. *IL-10* production involves intracellular Ca^{2+} and activation of the phospholipase C pathway. *IL-10* production also depends on activation of the novel PKC theta/delta, rather than conventional PKC isoforms.

Acknowledgments

This study was financially supported by Kumamoto Health Science University special fellowship grant No. 24-A-02. The authors declare that there are no conflicts of interest.

References

1. Meyer-Hoffert U. Neutrophil-derived serine proteases

- modulate innate immune responses. *Front Biosci (Landmark Ed)*. 2009; 14: 3409-3418.
2. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. *Nat Rev Immunol*. 2006; 6(7): 541-550.
 3. Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM, Gadek JE. Lung neutrophils in the adult respiratory distress syndrome. Clinical and pathophysiological significance. *Am Rev Respir Dis*. 1986; 133(2): 218-225.
 4. McGowan SE, Murray JJ. Direct effects of neutrophil oxidants on elastase-induced extracellular matrix proteolysis. *Am Rev Respir Dis*. 1987; 135(6): 1286-1293.
 5. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. *Am Rev Respir Dis*. 1990; 141(2): 471-501.
 6. Mainardi CL, Dasty DL, Seyer JM, Kang AH. Specific cleavage of human type III collagen by human polymorphonuclear leukocyte elastase. *J Biol Chem*. 1980; 255(24): 12006-12010.
 7. Compton SJ, Cairns JA, Palmer KJ, Al-Ani B, Hollenberg MD, Walls AF. A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. *J Biol Chem*. 2000; 275(50): 39207-39212.
 8. Kaufmann R, Schafberg H, Nowak G. Proteinase-activated receptor-2-mediated signaling and inhibition of DNA synthesis in human pancreatic cancer cells. *Int J Pancreatol*. 1998; 24(2): 97-102.
 9. Zhou J, Perelman JM, Kolosov VP, Zhou X. Neutrophil elastase induces MUC5AC secretion via protease-activated receptor 2. *Mol Cell Biochem*. 2013; 377(1-2): 75-85.
 10. Johansson U, Lawson C, Dabare M, Syndercombe-Court D, Newland AC, Howells GL, et al. Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-1 β . *J Leukoc Biol*. 2005; 78(4): 967-975.
 11. Nixon JS, Bishop J, Bradshaw D, Davis PD, Hill CH, Elliott LH, et al. Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity. *Drugs Exp Clin Res*. 1991; 17(8): 389-393.
 12. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, et al. Rottlerin, a novel protein kinase inhibitor. *Biochem Biophys Res Commun*. 1994; 199(1): 93-98.
 13. Xia J, Matsuhashi S, Hamajima H, Iwane S, Takahashi H, Eguchi Y, et al. The role of PKC isoforms in the inhibition of NF- κ B activation by vitamin K2 in human hepatocellular carcinoma cells. *J Nutr Biochem*. 2012; 23(12): 1668-1675.
 14. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. *J Biol Chem*. 1993; 268(13): 9194-9197.
 15. Chakraborti S, Roy S, Chowdhury A, Mandal A, Chakraborti T. Role of PKC α -p38 MAPK-Gi α axis in peroxynitrite-mediated inhibition of β -adrenergic response in pulmonary artery smooth muscle cells. *Cell Signal*. 2013; 25(2): 512-526.
 16. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Muller HJ, Johannes FJ. Inhibition of protein kinase C by various inhibitors. Differentiation from protein kinase C isoenzymes. *FEBS Lett*. 1996; 392(2): 77-80.
 17. Pal D, Outram SP, Basu A. Novel regulation of protein kinase C- η . *Biochem Biophys Res Commun*. 2012; 425(4): 836-841.
 18. Marte BM, Meyer T, Stabel S, Standke GJ, Jaken S, Fabro D, et al. Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-casein expression. *Cell Growth Differ*. 1994; 5(3): 239-247.
 19. Menne J, Shushakova N, Bartels J, Kiyan Y, Laudeley R, Haller H, et al. Dual inhibition of classical protein kinase C- α and protein kinase C- β isoforms protects against experimental murine diabetic nephropathy. *Diabetes*. 2013; 62(4): 1167-1174.
 20. Cole DC, Asselin M, Brennan A, Czerwinski R, Ellingboe JW, Fitz L, et al. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors. *J Med Chem*. 2008; 51(19): 5958-5963.
 21. Xiang B, Zhang G, Stefanini L, Bergmeier W, Gartner TK, Whiteheart SW, et al. The Src family kinases and protein kinase C synergize to mediate Gq-dependent platelet activation. *J Biol Chem*. 2012; 287(49): 41277-41287.
 22. Inada K, Endo S, Takahashi K, Suzuki M, Narita T, Yoshida T, et al. Establishment of a new perchloric acid treatment method to allow determination of the total endotoxin content in human plasma by the limulus test and clinical application. *Microbiol Immunol*. 1991; 35(4): 303-314.
 23. Kohno S, Mitsutake K, Maesaki S, Yasuoka A, Miyazaki T, Kaku M, et al. An evaluation of serodiagnostic tests in patients with candidemia: beta-glucan, mannan, candida antigen by Cand-Tec and D-arabinitol. *Microbiol Immunol*. 1993; 37(3): 207-212.
 24. Strieter RM, Remick DG, Lynch JP 3rd, Genord M, Rairford C, Spengler R, et al. Differential regulation of tumor necrosis factor- α in human alveolar macrophages and peripheral blood monocytes: a cellular and molecular analysis. *Am J Respir Cell Mo Biol*. 1989; 1(1): 57-63.
 25. Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. *Proc Natl Acad Sci USA*. 2005; 102(24): 8686-8691.
 26. Yule DI, Williams JA. U73122 inhibits Ca²⁺ oscillations in response to cholecystokinin and carbachol but not to JMV-180 in rat pancreatic acinar cells. *J Biol Chem*. 1992; 267(20): 13830-13835.
 27. Simpson AW, Hallam TJ, Rink TJ. TMB-8 inhibits secretion evoked by phorbol ester at basal cytoplasmic free calcium in quin2-loaded platelets much more effectively than it inhibits thrombin-induced calcium mobilization. *FEBS Lett*. 1984; 176(1): 139-143.
 28. Ibrahim IN, Hoover JM, Fields AM, Richards TA, Kaye AD. Influence of TMB-8 and thapsigargin on vasoconstrictor responses in the pulmonary vascular bed of the cat. *Am J Ther*. 2005; 12(5): 411-416.
 29. De Smet P, Parys JB, Callewaert G, Weidema AF, Hill E, De Smedt H, et al. Xestospongins C is an equally potent inhibitor of the inositol 1,4,5-trisphosphate receptor and the endoplasmic-reticulum Ca(2+) pumps. *Cell Calcium*. 1999; 26(1-2): 9-13.
 30. Ramachandran R, Mihara K, Chung H, Renaux B, Lau CS, Muruve DA, et al. Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). *J Biol Chem*. 2011; 286(28): 24638-24648.
 31. Shao MX, Nadel JA. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF- α -converting enzyme. *J Immunol*. 2005; 175(6): 4009-4016.
 32. Springael C, Thomas S, Rahmouni S, Vandamme A, Goldman M, Willems F, et al. Rottlerin inhibits human T cell responses. *Biochem Pharmacol*. 2007; 73(4): 515-525.
 33. Soltoff SP. Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. *Trends Pharmacol Sci*. 2007; 28(9): 453-458.